Solid Tumors Clinical Trial
Official title:
A Phase 1 Study Evaluating the Safety of ABT-263 in Combination With Etoposide/Cisplatin in Subjects With Cancer
NCT number | NCT00878449 |
Other study ID # | M10-234 |
Secondary ID | |
Status | Completed |
Phase | Phase 1 |
First received | |
Last updated | |
Start date | October 2009 |
Est. completion date | July 2011 |
Verified date | January 2013 |
Source | AbbVie |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a Phase 1 Study Evaluating the Safety of ABT-263 in Combination with Etoposide/Cisplatin in Subjects with Small Cell Lung Cancer (SCLC).
Status | Completed |
Enrollment | 12 |
Est. completion date | July 2011 |
Est. primary completion date | July 2011 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Must be greater then or equal to18 years of age; - For dose escalation subject must have histologically and/or cytologically documented cancer for which etoposide/cisplatin has been determined to be an appropriate therapy. For expanded safety cohort subject must have histologically and/or cytologically documented SCLC for which etoposide/cisplatin has been determined an appropriate therapy; - Subject has an ECOG performance score of less then or equal to 1; Evaluable and/or measurable disease by CT or MRI per RECIST criteria; - Subjects with brain metastases must have clinically controlled neurologic symptoms, defined as surgical excision and/or radiation therapy followed by 21 days of stable neurologic function and no evidence of CNS disease progression as determined by CT or MRI within 21 days prior to the 1st dose of study drug; - Must have adequate renal and hepatic function, per local laboratory reference range at Screening as follows: - ANC greater then or equal to 1500/mcL, - Platelets greater then or equal to 150,000/mm^3, - Hemoglobin greater then or equal to 10.0 g/dL, - Serum creatinine less then or equal to 1.5 mg/dL or calculated creatinine clearance greater then or equal to 50 mL/min; Na greater then 130 mmol/L, - Alkaline Phosphatase, AST and ALTless then or equal to 2.5 x ULN ;Bilirubin less then or equal to 1.5 x ULN.Subjects with liver mets may have ALP, AST and ALT less then or equal to 5.0 x ULN, Subjects with bone mets may have Alkaline Phosphatase less then or equal to 5.0 x ULN, - Subjects with Gilbert's Syndrome may have a Bilirubin greater then 1.5 x ULN, - Coagulation: aPTT, PT, less then or equal to 1.2 x ULN; - Life expectancy of at least 30 days; - Female subjects must be surgically sterile, postmenopausal (for at least 1 year), or have negative results for a pregnancy test; - Female subjects not surgically sterile or postmenopausal (for at least one year) and non-vasectomized male subjects must practice at least one method of birth control. Exclusion Criteria: - Subject exhibits evidence of other uncontrolled condition(s) including, but not limited to: active systemic infection, diagnosis of fever or neutropenia within 1 week of 1st dose; - Subject has an underlying, predisposing condition of bleeding or currently exhibits signs of bleeding; - Subject is currently receiving or requires anticoagulation therapy; - Subject has active immune thrombocytopenic purpura, autoimmune hemolytic anemia or a history of being refractory to platelet transfusions (within 1 year prior to 1st dose of study drug); - Subject has active peptic ulcer disease or other hemorrhagic esophagitis/gastritis; - Subject has a significant history of CV disease, renal, neurologic, psychiatric, endocrinologic, metabolic, immunologic, or hepatic disease; - Female subject is pregnant or breast-feeding; - Subject has tested positive for HIV; - Subject has a history of other active malignancies within 3 years prior to study entry, with the exception of: adequately treated in situ carcinoma of the cervix uteri, basal or squamous cell carcinoma of the skin, previous malignancy confined and surgically resected with curative intent; - Subject has received any anti-cancer therapy within 14 days prior to 1st dose of study drug; - Subject has received steroid therapy for anti-neoplastic intent within 7 days prior to 1st dose of study drug; - Subject has received aspirin within 7 days prior to 1st dose of study drug; - Subject has received radio-immunotherapy within 6 months prior to 1st dose of study drug; Subject has received an antibody therapy or other biologics (with the exception of colony stimulating factors [G-CSF,GM-CSF] or erythropoietin) within 28 days prior to 1st dose of study drug; - Subject has a hypersensitivity to platinum-containing compounds or etoposide; - Subject has consumed grapefruit within 3 days prior to 1st dose of study drug. |
Country | Name | City | State |
---|---|---|---|
United States | Site Reference ID/Investigator# 12303 | Baltimore | Maryland |
United States | Site Reference ID/Investigator# 12305 | Boston | Massachusetts |
United States | Site Reference ID/Investigator# 20381 | Boston | Massachusetts |
United States | Site Reference ID/Investigator# 13323 | Chicago | Illinois |
United States | Site Reference ID/Investigator# 43505 | Detroit | Michigan |
United States | Site Reference ID/Investigator# 12841 | Maywood | Illinois |
United States | Site Reference ID/Investigator# 13322 | New Brunswick | New Jersey |
Lead Sponsor | Collaborator |
---|---|
AbbVie (prior sponsor, Abbott) | Genentech, Inc. |
United States,
Pietanza MC, Rudin CM. Novel therapeutic approaches for small cell lung cancer: the future has arrived. Curr Probl Cancer. 2012 May-Jun;36(3):156-73. doi: 10.1016/j.currproblcancer.2012.03.005. Epub 2012 Apr 10. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Assess the safety profile of ABT-263 when administered in combination with etoposide/cisplatin in subjects with Cancer. | Weekly | ||
Primary | Characterize the pharmacokinetics of ABT-263 when administered in combination with etoposide/cisplatin . | Weekly | ||
Primary | Determine the maximum tolerable dose (MTD) of ABT-263 when administered in combination with etoposide/cisplatin. | Weekly | ||
Primary | Determine the recommended Phase 2 dose (RPTD) of ABT-263 when administered in combination with etoposide/cisplatin. | Weekly | ||
Secondary | Evaluate preliminary data regarding progression free survival (PFS). | Bi-monthly | ||
Secondary | Evaluate preliminary data regarding objective response rate (ORR). | Bi-monthly | ||
Secondary | Evaluate preliminary data regarding time to tumor progression (TTP). | Bi-monthly | ||
Secondary | Evaluate preliminary data regarding overall survival (OS). | Bi-monthly | ||
Secondary | Evaluate preliminary data regarding duration of overall response. | Bi-monthly | ||
Secondary | Evaluate preliminary data regarding Eastern Cooperative Oncology Group (ECOG) performance status. | Bi-monthly | ||
Secondary | Evaluate biomarkers | Define the relationship between disease state (related to patient selection and monitoring), B-Cell Lymphoma 2 (Bcl-2) family protein expression, and potential response to the proposed therapy ABT-263 and etoposide/cisplatin. | Bi-monthly |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT00750841 -
Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours
|
Phase 1 | |
Withdrawn |
NCT05419817 -
Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System
|
Phase 2 | |
Completed |
NCT02828930 -
A Study to Determine the Excretion Balance, Pharmacokinetics, Metabolism and Absolute Oral Bioavailability of a Single Oral Dose of [14C]-Labeled Idasanutlin and an Intravenous Tracer Dose of [13C]-Labeled Idasanutlin in a Single Cohort of Participants With Solid Tumors (Malignancies)
|
Phase 1 | |
Completed |
NCT01197170 -
Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance
|
Phase 1 | |
Completed |
NCT03258515 -
A Study to Investigate the Effect of Single Dose of AZD6094 (600 mg) on Cardiac Repolarization in Healthy Volunteers
|
Phase 1 | |
Terminated |
NCT03225105 -
M3541 in Combination With Radiotherapy in Solid Tumors
|
Phase 1 | |
Completed |
NCT01497925 -
Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer
|
Phase 1 | |
Completed |
NCT01878890 -
Phase I Dose Escalation Trial of Efavirenz in Solid Tumours or Non-Hodgkin Lymphoma in Therapeutic Failure.
|
Phase 1 | |
Active, not recruiting |
NCT05059522 -
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
|
Phase 3 | |
Active, not recruiting |
NCT03634982 -
Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors
|
Phase 1 | |
Recruiting |
NCT04685226 -
A Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
Recruiting |
NCT06036121 -
A Study of ADRX-0706 in Select Advanced Solid Tumors
|
Phase 1 | |
Active, not recruiting |
NCT03258151 -
Association of Genetic Polymorphisms With Docetaxel-based Chemotherapy Toxicities in Chinese Solid Tumor Patients
|
||
Completed |
NCT01528046 -
Metformin in Children With Relapsed or Refractory Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05325866 -
A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
|
Phase 1/Phase 2 | |
Recruiting |
NCT04557449 -
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
|
Phase 1/Phase 2 | |
Terminated |
NCT02890368 -
Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides
|
Phase 1 | |
Completed |
NCT02759640 -
A Phase I Trial of HS-10241 in Solid Tumors
|
Phase 1 | |
Completed |
NCT02279433 -
A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b
|
Phase 1 |